CODX241206C500
- 0.00
- 0.000.00%
Co-diagnostics Newsroom
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.
US pharmaceutical stocks plummet, has the market overreacted to Little Kennedy?
Source: Analysis from Wall Street News states that even if Kennedy is confirmed as the Secretary of Health in the usa, he may not be able to "make a big impact". First, there may be divisions within Trump's team; secondly, it is uncertain whether Kennedy has the authority to appoint leaders of departments like the FDA; finally, Trump may appoint individuals with industry backgrounds as FDA commissioners, directing Kennedy's attention to focus on nutrition rather than pharmaceutical approvals. The famous "anti-vaccine pioneer" and advocate for healthy eating, the new government-nominated Secretary of Health Robert Kennedy, is dining with the loyal "fast food enthusiast" Trump, who promotes rapid vaccine development.
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
First Mpox Case Linked to African Outbreak Reported in U.S.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
H.C. Wainwright Maintains Co-diagnostics(CODX.US) With Hold Rating, Maintains Target Price $1.5
HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $1.5 Price Target
Cautious Outlook: Co-Diagnostics Hold Rating Amid Revenue Decline and Regulatory Uncertainties
Co-Diagnostics Analyst Ratings
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Summary
Co-Diagnostics GAAP EPS of -$0.32 Beats by $0.01, Revenue of $0.64M Beats by $0.26M
Earnings Flash (CODX) CO-DIAGNOSTICS Posts Q3 Revenue $641,141
Co-diagnostics | 10-Q: Q3 2024 Earnings Report
Co-diagnostics | 8-K: Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results
Express News | Co-Diagnostics Q3 Revenue USD 600 Thousand
Co-Diagnostics 3Q Loss/Shr 32c >CODX